Cerus Corp (CERS) Stock Price, Quote & News

Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets an...

Industry: Medical Devices

Sector: Healthcare

Phone: 925 288 6000

Website: www.cerus.com

Address:

1220 Concord Avenue, Suite 600, Concord, United States

Sw1ngb0t Nov. 12 at 12:34 PM

$CERS $2.04+

0 · Reply

Me0wth Nov. 11 at 7:17 PM

$AKBA $BCRX $CERS $CHRS $ESPR 1 year bio tech challenge. 5 bio techs, 1000 dollars in each. No adding, no selling for 1 year. Started on November 29, 2024 Was up nicely until AKBA got destroyed 😹 a few more weeks to go

4 · Reply

huma_44 Nov. 11 at 5:36 PM

$CERS strong after Q3 ER

0 · Reply

Violenteer Nov. 11 at 3:23 PM

$CERS Im targeting at least 3.

0 · Reply

StockBraker Nov. 11 at 2:54 PM

$CERS

0 · Reply

Stockttwits619 Nov. 10 at 5:41 PM

$RUBI $CHEK $OP $CERS

0 · Reply

bryantvsu Nov. 9 at 10:35 PM

$CERS Friends! Can you see short-term run for 2 or 3 dollars? Wall Street Zen has upgraded Cerus from "hold" to Buy. Shares were trading up 21.3% (opened at $1.71) with a market cap of $327.8M and a negative PE (-17.1), highlighting volatility and a low valuation. Recent Q2 results showed EPS of -$0.03 (missed estimates by $0.01) but revenue of $60.1M beat expectations, and institutional ownership is high at 78.37% with several hedge funds increasing stakes. Do your own homework friends. Enjoy!

1 · Reply

BioGem Nov. 9 at 11:42 AM

$CERS I reentered this stock at $1.5. Finally, they are on better financial footing and steadily closer to profitability. -Beat Revenue and EPS estimates. -Cash breakeven achieved. -Raised guidance, which increases their fair value to the $1.8 range and that is without RBC approval. -The RBC approval is like an option with huge upside. -Momentum has picked up = recognized by large funds. -Short interest has dropped. -Expect analysts to increase price targets. $XBI $IBB

0 · Reply

Stockttwits619 Nov. 7 at 9:40 PM

$RUBI $CHEK $OP $CERS I TOOK 10% on CHEK 😎

0 · Reply

VolumePrice Nov. 7 at 8:54 PM

$CERS second half of 2026 will be interesting

0 · Reply

Cerus Corporation (CERS) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:01 PM EST - 8 days ago

Cerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance

Oct 21, 2025, 8:30 AM EDT - 24 days ago

Cerus Corporation Announces Abstracts and Industry Workshop on IFC at the 2025 AABB Annual Meeting

Oct 16, 2025, 4:00 PM EDT - 4 weeks ago

Cerus Corporation to Release Third Quarter 2025 Financial Results on November 6, 2025

Aug 25, 2025, 9:00 AM EDT - 2 months ago

The German National Blood Advisory Committee Issues Formal Recommendation for Improving the Safety of Platelet Transfusions

Aug 21, 2025, 8:30 AM EDT - 3 months ago

Cerus Corporation to Participate in the Cantor Global Healthcare Conference 2025

Aug 5, 2025, 9:02 PM EDT - 3 months ago

Cerus Corporation (CERS) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:01 PM EDT - 3 months ago

Cerus Corporation Announces Second Quarter 2025 Financial Results

Jul 22, 2025, 4:15 PM EDT - 4 months ago

Cerus Corporation to Release Second Quarter 2025 Financial Results on August 5, 2025

Jul 21, 2025, 8:30 AM EDT - 4 months ago

Cerus Corporation Announces Additional Department of Defense Award to Advance Care for Major Hemorrhage in Traumatic Injury

Jul 2, 2025, 8:30 AM EDT - 4 months ago

Cerus Corporation Provides INTERCEPT Red Blood Cell CE Mark Application Update

Jun 13, 2025, 4:01 PM EDT - 5 months ago

Cerus Corporation Celebrates World Blood Donor Day 2025

Jun 3, 2025, 4:30 PM EDT - 5 months ago

Cerus Corporation to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 29, 2025, 8:30 AM EDT - 6 months ago

Cerus Corporation Presents Clinical Data for INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion Congress in Milan

May 28, 2025, 8:30 AM EDT - 6 months ago

Cerus Corporation Announces Multiple In-Country Regulatory Approvals for INT200 – Next-Generation INTERCEPT Illumination Device

May 1, 2025, 8:26 PM EDT - 7 months ago

Cerus Corporation (CERS) Q1 2025 Earnings Call Transcript

May 1, 2025, 4:00 PM EDT - 7 months ago

Cerus Corporation Announces First Quarter 2025 Financial Results

Apr 17, 2025, 8:30 AM EDT - 7 months ago

Cerus Corporation to Release First Quarter 2025 Financial Results on May 1, 2025

Mar 5, 2025, 1:00 PM EST - 9 months ago

Cerus Corporation Announces Receipt of CE Mark for Next-Generation INTERCEPT Illumination Device (INT200)

Feb 20, 2025, 9:50 PM EST - 9 months ago

Cerus Corporation (CERS) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 4:00 PM EST - 9 months ago

Cerus Corporation Announces Full-Year and Fourth Quarter 2024 Financial Results

Feb 19, 2025, 4:00 PM EST - 9 months ago

Cerus Corporation to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 7, 2025, 8:30 AM EST - 10 months ago

Cerus Corporation to Release Fourth Quarter and Full-Year 2024 Financial Results on February 20, 2025

Jan 13, 2025, 8:30 AM EST - 10 months ago

Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2024 Product Revenue and Provides Business Update

Nov 13, 2024, 8:30 AM EST - 1 year ago

Cerus Corporation to Participate in Upcoming Investor Conferences

Oct 30, 2024, 11:52 PM EDT - 1 year ago

Cerus Corporation (CERS) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 4:00 PM EDT - 1 year ago

Cerus Corporation Announces Third Quarter 2024 Financial Results

Oct 18, 2024, 8:30 AM EDT - 1 year ago

Cerus Corporation to Release Third Quarter 2024 Financial Results on October 30, 2024

Oct 18, 2024, 8:30 AM EDT - 1 year ago

Cerus Corporation Announces Workshop and Abstracts at the 2024 AABB Annual Meeting

Oct 16, 2024, 4:00 PM EDT - 1 year ago

Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe

Aug 1, 2024, 8:29 PM EDT - 1 year ago

Cerus Corporation (CERS) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:00 PM EDT - 1 year ago

Cerus Corporation Announces Second Quarter 2024 Financial Results and Increases Full-Year 2024 Product Revenue Guidance Range

Jul 18, 2024, 8:30 AM EDT - 1 year ago

Cerus Corporation to Release Second Quarter 2024 Financial Results on August 1, 2024

Jul 2, 2024, 4:00 PM EDT - 1 year ago

Cerus Corporation Announces Appointment of Dean Gregory to Board of Directors

Jun 21, 2024, 8:30 AM EDT - 1 year ago

Cerus Corporation Announces Symposium and Abstracts at the 38th International Congress of the International Society of Blood Transfusion

Jun 14, 2024, 8:30 AM EDT - 1 year ago

Cerus Corporation Celebrates World Blood Donor Day 2024

May 22, 2024, 8:30 AM EDT - 1 year ago

Cerus Corporation to Participate in 21st Annual Craig-Hallum Institutional Investor Conference

May 2, 2024, 7:37 PM EDT - 1 year ago

Cerus Corporation (CERS) Q1 2024 Earnings Call Transcript

May 2, 2024, 4:00 PM EDT - 1 year ago

Cerus Corporation Announces First Quarter 2024 Financial Results

Apr 18, 2024, 8:30 AM EDT - 1 year ago

Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024

Mar 26, 2024, 8:30 AM EDT - 1 year ago

Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life

Mar 19, 2024, 8:00 AM EDT - 1 year ago

Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients

Mar 5, 2024, 6:43 PM EST - 1 year ago

Cerus Corporation (CERS) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 4:00 PM EST - 1 year ago

Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results

Feb 20, 2024, 8:30 AM EST - 1 year ago

Cerus Corporation to Release Fourth Quarter and Full-Year 2023 Financial Results on March 5, 2024

Jan 8, 2024, 8:30 AM EST - 2 years ago

Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2023 Product Revenue and Provides Business Update

Nov 2, 2023, 10:52 PM EDT - 2 years ago

Cerus Corporation (CERS) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 4:00 PM EDT - 2 years ago

Cerus Corporation Announces Third Quarter 2023 Financial Results

Nov 1, 2023, 2:46 PM EDT - 2 years ago

Bloodbuy Announces Agreement with Cerus Corporation to Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex on its Digital Marketplace

Oct 19, 2023, 8:30 AM EDT - 2 years ago

Cerus Corporation to Release Third Quarter 2023 Financial Results on November 2, 2023

Sw1ngb0t Nov. 12 at 12:34 PM

$CERS $2.04+

0 · Reply

Me0wth Nov. 11 at 7:17 PM

4 · Reply

huma_44 Nov. 11 at 5:36 PM

$CERS strong after Q3 ER

0 · Reply

Violenteer Nov. 11 at 3:23 PM

$CERS Im targeting at least 3.

0 · Reply

StockBraker Nov. 11 at 2:54 PM

$CERS

0 · Reply

Stockttwits619 Nov. 10 at 5:41 PM

$RUBI $CHEK $OP $CERS

0 · Reply

bryantvsu Nov. 9 at 10:35 PM

1 · Reply

BioGem Nov. 9 at 11:42 AM

0 · Reply

Stockttwits619 Nov. 7 at 9:40 PM

$RUBI $CHEK $OP $CERS I TOOK 10% on CHEK 😎

0 · Reply

VolumePrice Nov. 7 at 8:54 PM

$CERS second half of 2026 will be interesting

0 · Reply

VolumePrice Nov. 7 at 8:38 PM

$CERS I see kind of reverse head and shoulder :)

0 · Reply

VolumePrice Nov. 7 at 8:32 PM

$CERS market liked the earning, if holding 1.68 as support, that will be a good technical sign

0 · Reply

Stockttwits619 Nov. 7 at 8:08 PM

$RUBI $CHEK $OP $CERS THEYRE ALL UP WOW ✌️

0 · Reply

N8LongShort Nov. 7 at 7:36 PM

$CERS markets pricing in future profitability

0 · Reply

StockBraker Nov. 7 at 7:19 PM

$CERS Hey @BeefStewart - How are you feeling today about Cerus?

1 · Reply

Stockttwits619 Nov. 7 at 6:44 PM

$RUBI 👀👀👀👀 $CHEK $OP $CERS likely to trend usual suspects are trending

0 · Reply

OldManLogan Nov. 7 at 3:16 PM

$CERS The market certainly disagrees with you, lol. And why shouldn't they, you have to be on some special drugs to say that a company that just delivered both a topline and bottom line beat has issued a very negative ER, lmao. It's an excellent release and CERS longs should be very happy with the progress toward profitability that's being made.

0 · Reply

Robol Nov. 7 at 2:46 PM

$CERS

0 · Reply

Love_To_Learn Nov. 7 at 1:03 PM

$RCAT will use the CAT portion of your name for part of the name for project with DON n Puerto Rico isolating R for markets R CELLS $RCEL accessing $CERS $GRFS

1 · Reply

BullMaven Nov. 7 at 3:49 AM

$CERS

0 · Reply

d_risk Nov. 7 at 3:26 AM

$CERS - Cerus Corporation Common Stock - 10Q - Updated Risk Factors CERS’s latest 10-Q risk factors spotlight heightened manufacturing and supply chain vulnerabilities, expanded risks in U.S. commercialization and market concentration, intensified competition, regulatory and clinical trial hurdles, new data privacy and government contract uncertainties, and financial pressures from ongoing losses and funding needs. #Biotechnology #FinancialPressure #MarketCompetition #RegulatoryChallenges #SupplyChainRisk 🟢 Added 🟠 Removed https://d-risk.ai/CERS/10-Q/2025-11-06

0 · Reply

SFstockjock Nov. 6 at 9:28 PM

$CERS Guys, hate to burst bubbles here, but this release is very negative – absent some sort of news on the call, expect the stock to get hit tomorrow: - IFC is down 30% over the second quarter (and they guided down IFC revenue for the full year) - Gross margin is down 2% from 2Q25 (that annualizes to a $4M cash flow hit) - G&A and R&D expenses up - Full year guidance taken up a meaningless $1M

2 · Reply

Market Cap	307.34M
Revenue (ttm)	201.32M
Net Income (ttm)	-20.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-10.39%
Debt to Equity Ratio	1.37

Volume	1,028,700
Avg Vol	1,407,256
Day's Range	N/A - N/A
Shares Out	192.09M
Stochastic %K	60%
Beta	1.67
Analysts	Strong Sell
Price Target	$4.67